Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Open Source Software
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Login and Edit functionaility are currrently unavailable.
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.
Xenograft Model Antitumor Assays
Targeting MYCN in neuroblastoma by BET bromodomain inhibition.
Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.
Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist.
The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models.
Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer.
Targeting DOT1L for Degradation in MLL-rearranged Leukemia
Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts.
Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
BET bromodomain is a novel regulator of TAZ and its activity.
Transcriptional and Epigenetic Adaptation as Novel Therapeutic Vulnerabilities for Mantle Cell Lymphoma